Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04181788
Recruitment Status : Recruiting
First Posted : November 29, 2019
Last Update Posted : June 11, 2021
Sponsor:
Information provided by (Responsible Party):
Pfizer

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : May 6, 2022
Estimated Study Completion Date : May 7, 2025